Comparative Pharmacology
Head-to-head clinical analysis: CERETEC versus XENOVIEW.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CERETEC versus XENOVIEW.
CERETEC vs XENOVIEW
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium-99m exametazime (Ceretec) is a lipophilic radiopharmaceutical that crosses the blood-brain barrier and is taken up by brain tissue in proportion to regional cerebral blood flow. Once inside cells, it undergoes intracellular conversion to a hydrophilic form, trapping it in the brain and allowing SPECT imaging.
Xenoview is a paramagnetic contrast agent for MRI that enhances T1 relaxation by shortening the longitudinal relaxation time of water protons in tissues where it accumulates, thereby increasing signal intensity on T1-weighted images.
555-740 MBq (15-20 mCi) intravenously as a single dose for SPECT imaging.
Not applicable (diagnostic agent, not therapeutic); refer to imaging protocol.
None Documented
None Documented
Terminal: 6 hours (range 4–8 h); clinical: supports twice-daily dosing in nuclear medicine studies.
Terminal elimination half-life is 3-5 hours in patients with normal renal function; may be prolonged in renal impairment.
Renal: 40% unchanged; biliary/fecal: 60% (as metabolites and parent compound).
Primarily renal excretion (60-70% unchanged drug), with 20-25% biliary/fecal elimination.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical